Patent SG-11201810196R-A (SG)
Title: Cancer treatments
Inventor: GRIFFITH HUGH
IPC: A61K31/7076
Filed: 2017-05-31
Abstract: INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property MD 1101/110 DOI 010111110101111 0 0111111111111111111111111111111111111111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......0\" WO 2017/207993 Al 07 December 2017 (07.12.2017) WIP0 I PCT (51) International Patent Classification: A61K 31/7064 (2006.01) A61P 35/00 (2006.01) Declarations under Rule 4.17: A61K 31/7072 (2006.01) A61P 35/02 (2006.01) — of inventorship (Rule 4.17(iv)) A61K 31/7076 (2006.01) Published: (21) International Application Number: — with international search report (Art. 21(3)) PCT/GB2017/051560 (22) International Filing Date: 31 May 2017 (31.05.2017) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 1609600.0 01 June 2016 (01.06.2016) GB (71) Applicant: NUCANA BIOMED LIMITED [GB/GB]; 10 Lochside Place, Edinburgh Scotland EH12 9RG (GB). (72) Inventor: MCGUIGAN, Chris (deceased). (72) Inventors: GRIFFITH, Hugh; c/o Nucana BioMed Lim- ited, 10 Lochside Place, Edinburgh EH12 9RG (GB). PEP- PER, Chris; Dean of Research, School of Medicine, Cardiff University, Heath Park, Cardiff CF14 4XN (GB). (74) Agent: HGF LIMITED; 4th Floor, Merchant Exchange, 17-19 Whitworth Street West, Manchester Greater Man- chester Ml 5WG (GB). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind ARIPO GH, of regional protection available): (BW, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, 1-1 KM, ML, MR, NE, SN, TD, TG). M C:r IN CN (54) Title: CANCER TREATMENTS 0 (57) : Provided are medical uses and methods for targeting cancer stem cells employing ProTide compounds, particularly in ei ----. the prevention or treatment of cancer. The ProTide may be other than one selected from the group consisting of: NUC-1031; a ProTide IN derived from cordycepin; and a ProTide derived from 8-chloroadenosine. The medical uses and methods for targeting cancer stem © cells are particularly useful in the treatment of relapsed or refractory cancer in human patients. The invention also provides methods N of selecting patients who will benefit from prevention or treatment of cancer through the medical uses or methods of treatment of the 0 invention.